

March 28th, 2024

The Honourable Mark Holland Minister of Health Ministry of Health 5th Floor, 777 Bay Street, Toronto, ON M5G 2C8

Dear The Honourable Mark Holland,

The signatories to this letter request a Federal, Provincial, and Territorial (FPT) collaboration with the Canadian health and clinical scientific community to implement a pan-Canadian monitoring system for major risk factors for cardiovascular disease.

According to the latest data from 2019, cardiovascular disease caused over 80,000 deaths and 1,452,000 years of disability (DALYs) in Canada. Each year, increasing numbers of Canadians are dying of cardiovascular disease and the numbers of Canadians suffering from cardiovascular-related disability are increasing rapidly. Cardiovascular diseases are highly preventable with cost effective public health and clinical interventions, but progress in prevention has stalled in recent years. The current surveillance system collects most of the relevant data but how these data are analyzed and reported is an obstacle to implement strategies and take timely actions to optimize preventative health care delivery.

We propose a monitoring system based on the existing surveillance system with the analysis developed collaboratively with scientific community and reported on an annual basis. The new system, based on a partnership between FPTs and the health care and clinical scientific sector, would assess hypertension, diabetes, smoking, obesity, dyslipidemia (i.e., high cholesterol), preeclampsia (and eclampsia), physical inactivity, and alcohol consumption. It would report on the number of Canadians with these health risks and, where appropriate, whether the risk has been clinically diagnosed, treated, and controlled.

The Canadian health and scientific community look forward to a new collaborative interaction with FPT governments to enhance the health, wellness and productivity of Canadians. This collaboration is particularly important with the COVID-19 pandemic as people with cardiovascular risks and disease are at higher risk of morbidity and mortality when infected with COVID-19. The manner in which health care is delivered was also dramatically altered by the pandemic (e.g., about 50% fewer follow-up visits) and as such, monitoring and evaluation are of even greater importance to assess best practices and learnings from these changes.

We ask that federal government convene a FPT roundtable on cardiovascular disease, inviting health care and clinical science leaders from across Canada, with an aim of developing and implementing a collaborative monitoring system.



If you have any questions, please contact <u>anna.stoutenburg@hypertension.ca</u>. We look forward to hearing from you. More details, background, and rationale are attached as an appendix.

Thanks,

Dr. Norm Campbell CM MD DSc (hon) FRCPC (Interim Chair, Canadian Hypertension Coalition)

Dr. Ross T. Tsuyuki, BSc (Pharm), PharmD, MSc, FC SHP, FACC, FCAHS

President, Hypertension Canada

RIM

Mylll

Patrice Lindsay

Lead, Engagement and Stroke Strategies Heart and Stroke Foundation of Canada

Kara Nerenberg, MD, MSc, FRCPC

Chair, Canadian Postpregnancy Clinical Network



Sheldon Tobe

Co-Chair C-CHANGE

(Canadian Cardiovascular National Guidelines Endeavour)



Robert L. Myette, MS, MD, FRCPC Pediatric Nephrologist, Medical Director of Dialysis Children's Hospital of Eastern Ontario

Kristen Pederson MD FRCPC

President, Canadian Association of Pediatric Nephrologists



Shil

Diamond Fernandes BSc, ACSM, FAAMM President of CACPR





Chuttany/

Christina (Chris) Kuttnig, RN, BN, CCN(C) (she/her)
President — Canadian Council of Cardiovascular Nurses

Sylvie Lauzon, President & CEO Diabetes Québec

Jeff Critch, MD FRCPC President, Canadian Paediatric Society

Steven Shadowitz

Dr. Steven Shadowitz President, Canadian Society of Internal Medicine

Glenn Thibeault

Executive Director, Government Affairs, Advocacy & Policy

Diabetes Canada